TMEM200B and neoplasm: The pooled analysis revealed a positive benefit‐risk profile with higher response rates and longer duration of response achieved in patients with tTMB‐high tumors that supports the use of a 1200‐mg, every‐3‐week regimen of atezolizumab in a tumor‐agnostic high‐tTMB population.